U.S. Markets closed
  • S&P 500

    3,934.38
    -29.13 (-0.73%)
     
  • Dow 30

    33,476.46
    -305.02 (-0.90%)
     
  • Nasdaq

    11,004.62
    -77.39 (-0.70%)
     
  • Russell 2000

    1,796.66
    -21.63 (-1.19%)
     
  • Crude Oil

    71.59
    +0.13 (+0.18%)
     
  • Gold

    1,809.40
    +7.90 (+0.44%)
     
  • Silver

    23.68
    +0.43 (+1.87%)
     
  • EUR/USD

    1.0545
    -0.0014 (-0.1371%)
     
  • 10-Yr Bond

    3.5670
    +0.0760 (+2.18%)
     
  • Vix

    22.83
    +0.54 (+2.42%)
     
  • GBP/USD

    1.2250
    +0.0012 (+0.0980%)
     
  • USD/JPY

    136.5500
    -0.0800 (-0.0586%)
     
  • BTC-USD

    17,155.48
    -58.54 (-0.34%)
     
  • CMC Crypto 200

    402.11
    -4.14 (-1.02%)
     
  • FTSE 100

    7,476.63
    +4.46 (+0.06%)
     
  • Nikkei 225

    27,901.01
    +326.58 (+1.18%)
     

EU regulators can examine Illumina, Grail deal, EU court says

LUXEMBOURG, July 13 (Reuters) - EU antitrust regulators can scrutinise U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail following a request from France and other EU countries, Europe's second-top court said on Wednesday.

The case is important for EU antitrust chief Margrethe Vestager who wants to expand the European Commission's power to examine big companies' acquisitions of start-ups aimed at shutting down nascent rivals, particularly in tech and pharma deals.

"The Commission has the competence to examine that concentration which did not have a European dimension or fall within the scope of the national merger control rules of member states of the European Union or states party to the agreement on the European Economic Area," the General Court said.

The case is T-227/21 Illumina v Commission. (Reporting by Foo Yun Chee and Marine Strauss;)